This article was originally published in The Tan Sheet
"It is insupportable that in some cases FDA has given information about major policy matters to the press before providing the same information to Congress," according to a House conference report accompanying the omnibus spending bill. The report stresses the agency should advise the committees of any changes regarding drug safety. Report language stems from FDA's handling of safety concerns regarding Vioxx and antidepressants...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."